William Blair Has Positive Estimate for MRSN Q2 Earnings

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Research analysts at William Blair upped their Q2 2025 earnings per share (EPS) estimates for shares of Mersana Therapeutics in a report released on Thursday, May 15th. William Blair analyst A. Hsieh now expects that the company will post earnings of ($0.18) per share for the quarter, up from their previous estimate of ($0.21). William Blair has a “Outperform” rating on the stock. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. William Blair also issued estimates for Mersana Therapeutics’ Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.76) EPS.

A number of other brokerages have also recently commented on MRSN. Truist Financial increased their target price on Mersana Therapeutics from $9.00 to $10.00 and gave the company a “buy” rating in a report on Friday. Guggenheim reiterated a “buy” rating and set a $5.00 target price on shares of Mersana Therapeutics in a report on Friday. Finally, Wedbush reiterated an “outperform” rating and set a $3.00 target price on shares of Mersana Therapeutics in a report on Thursday, May 15th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $5.20.

Mersana Therapeutics Price Performance

Shares of NASDAQ:MRSN opened at $0.39 on Monday. The business’s fifty day moving average price is $0.37 and its two-hundred day moving average price is $0.99. The stock has a market cap of $47.98 million, a PE ratio of -0.63 and a beta of 1.32. The company has a debt-to-equity ratio of 13.35, a quick ratio of 2.35 and a current ratio of 2.35. Mersana Therapeutics has a one year low of $0.26 and a one year high of $2.83.

Mersana Therapeutics (NASDAQ:MRSN) last announced its earnings results on Thursday, May 15th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. The firm had revenue of $2.75 million for the quarter, compared to analysts’ expectations of $6.05 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%.

Institutional Trading of Mersana Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of MRSN. AQR Capital Management LLC bought a new stake in Mersana Therapeutics in the first quarter valued at about $1,770,000. Novo Holdings A S bought a new stake in Mersana Therapeutics in the fourth quarter valued at about $6,078,000. Boxer Capital Management LLC bought a new stake in Mersana Therapeutics in the fourth quarter valued at about $3,768,000. 683 Capital Management LLC increased its holdings in Mersana Therapeutics by 83.3% in the first quarter. 683 Capital Management LLC now owns 1,650,000 shares of the company’s stock valued at $568,000 after buying an additional 750,000 shares during the last quarter. Finally, Ieq Capital LLC bought a new stake in Mersana Therapeutics in the first quarter valued at about $243,000. 93.92% of the stock is owned by institutional investors.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.